Comparative Pharmacology
Head-to-head clinical analysis: JYLAMVO versus LYNAVOY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JYLAMVO versus LYNAVOY.
JYLAMVO vs LYNAVOY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.
None Documented
None Documented
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 30–40 hours, supporting once-daily dosing. Steady-state is achieved within 2–3 weeks.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Primarily via bile into feces (approximately 77% of total clearance as unchanged drug and metabolites); renal excretion accounts for about 15% (less than 1% unchanged). A small amount is excreted in urine as metabolites.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent